BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors

Source : https://www.jci.org/articles/view/133090

The bromodomain and extra-terminal domain (BET) proteins are promising therapeutic targets to treat refractory solid tumors; however, inherent resistance remains a major challenge in the clinic. Recently, the emerging role of the oncoprotein B cell lymphoma 6 (BCL6) in tumorigenesis and stress response has been unveiled.